Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention.
暂无分享,去创建一个
[1] S. Carter,et al. Anthracycline Antibiotics in Cancer Therapy , 1982, Developments in Oncology.
[2] P. Trail,et al. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. , 1997, Cancer research.
[3] P. Volberding,et al. Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma , 1996, Journal of clinical pharmacology.
[4] L. Murray,et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[6] J. Folkman. New perspectives in clinical oncology from angiogenesis research. , 1996, European journal of cancer.